Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Operating Expenses (2016 - 2025)

KalVista Pharmaceuticals' Other Operating Expenses history spans 4 years, with the latest figure at -$9.6 million for Q1 2017.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$9.6 million in Q1 2017 year-over-year; TTM through Oct 2017 was -$9.6 million, a 755.07% decrease, with the full-year FY2025 number at -$53.4 million, down 49.25% from a year prior.
  • Other Operating Expenses hit -$9.6 million in Q1 2017 for KalVista Pharmaceuticals, down from $1000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for KALV hit a ceiling of $3.8 million in Q4 2014 and a floor of -$9.6 million in Q1 2017.
  • Historically, Other Operating Expenses has averaged -$855800.0 across 4 years, with a median of $1000.0 in 2016.
  • The widest YoY moves for Other Operating Expenses: up 100.03% in 2015, down 100.03% in 2015.
  • Tracing KALV's Other Operating Expenses over 4 years: stood at $3.8 million in 2014, then crashed by 100.03% to -$1000.0 in 2015, then skyrocketed by 200.0% to $1000.0 in 2016, then crashed by 956500.0% to -$9.6 million in 2017.
  • Business Quant data shows Other Operating Expenses for KALV at -$9.6 million in Q1 2017, $1000.0 in Q4 2016, and $1.5 million in Q1 2016.